JP2018027923A - ケトン体生成促進用組成物 - Google Patents
ケトン体生成促進用組成物 Download PDFInfo
- Publication number
- JP2018027923A JP2018027923A JP2016161267A JP2016161267A JP2018027923A JP 2018027923 A JP2018027923 A JP 2018027923A JP 2016161267 A JP2016161267 A JP 2016161267A JP 2016161267 A JP2016161267 A JP 2016161267A JP 2018027923 A JP2018027923 A JP 2018027923A
- Authority
- JP
- Japan
- Prior art keywords
- chain fatty
- fatty acid
- medium chain
- composition
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002576 ketones Chemical class 0.000 title claims abstract description 90
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 42
- 230000001737 promoting effect Effects 0.000 title claims abstract description 30
- 150000004667 medium chain fatty acids Chemical class 0.000 claims abstract description 68
- 235000001014 amino acid Nutrition 0.000 claims abstract description 66
- 150000001413 amino acids Chemical class 0.000 claims abstract description 65
- 150000002711 medium chain fatty acid esters Chemical class 0.000 claims abstract description 41
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims abstract description 36
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims abstract description 27
- 235000013477 citrulline Nutrition 0.000 claims abstract description 27
- 229960002173 citrulline Drugs 0.000 claims abstract description 27
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 22
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 16
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000005772 leucine Nutrition 0.000 claims abstract description 15
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims abstract description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 10
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 8
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000018417 cysteine Nutrition 0.000 claims abstract description 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960003080 taurine Drugs 0.000 claims abstract description 8
- 229940024606 amino acid Drugs 0.000 claims description 65
- 235000013305 food Nutrition 0.000 claims description 47
- 238000004519 manufacturing process Methods 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 230000002265 prevention Effects 0.000 claims description 18
- 229960003136 leucine Drugs 0.000 claims description 14
- 208000024891 symptom Diseases 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 9
- 108091006296 SLC2A1 Proteins 0.000 claims description 7
- 229960005261 aspartic acid Drugs 0.000 claims description 7
- 229960002433 cysteine Drugs 0.000 claims description 7
- 229960002743 glutamine Drugs 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 5
- 230000007812 deficiency Effects 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 206010003805 Autism Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 claims description 3
- 108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 claims description 3
- 206010040981 Sleep attacks Diseases 0.000 claims description 3
- 230000005856 abnormality Effects 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 79
- 239000008280 blood Substances 0.000 description 56
- 210000004369 blood Anatomy 0.000 description 56
- 239000003795 chemical substances by application Substances 0.000 description 43
- 239000003921 oil Substances 0.000 description 22
- 235000019198 oils Nutrition 0.000 description 22
- 238000001727 in vivo Methods 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 15
- 230000037396 body weight Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 239000003925 fat Substances 0.000 description 10
- 230000037406 food intake Effects 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 9
- -1 amino acid salts Chemical class 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 235000013350 formula milk Nutrition 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000020887 ketogenic diet Nutrition 0.000 description 3
- 235000021056 liquid food Nutrition 0.000 description 3
- 150000004668 long chain fatty acids Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000005643 Pelargonic acid Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 1
- OJFDKHTZOUZBOS-CITAKDKDSA-N acetoacetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 OJFDKHTZOUZBOS-CITAKDKDSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000021074 carbohydrate intake Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000014651 chocolate spreads Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000011306 frozen processed food Nutrition 0.000 description 1
- 235000013569 fruit product Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000020855 low-carbohydrate diet Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000018984 mastication Effects 0.000 description 1
- 238000010077 mastication Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229940000673 orphan drug Drugs 0.000 description 1
- 239000002859 orphan drug Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
[1]シトルリン、ロイシン、システイン、タウリン、グルタミンおよびアスパラギン酸からなる群から選択される1種または2種以上のアミノ酸を有効成分として含んでなる、ケトン体生成促進用組成物およびケトン体生成促進剤。
[2]中鎖脂肪酸および中鎖脂肪酸エステルのいずれかまたは両方をさらに含んでなる、前記[1]に記載の組成物および用剤。
[3]中鎖脂肪酸エステルが中鎖脂肪酸トリグリセリドである、前記[1]または[2]に記載の組成物および用剤。
[4]アミノ酸(A)の中鎖脂肪酸および中鎖脂肪酸エステル(B)に対するモル比[(A)/(B)]が0.1〜0.5である、前記[2]または[3]に記載の組成物および用剤。
[5]食品組成物である、前記[1]〜[4]のいずれかに記載の組成物および用剤。
[6]ケトン体生成促進がその治療、予防または改善に有効である疾患または症状の治療、予防または改善に用いるための、前記[1]〜[5]のいずれかに記載の組成物および用剤。
[7]前記疾患および症状が、小児てんかん、難治性てんかん、グルコーストランスポーター1(GLUT1)欠損症、ピルビン酸脱水素酵素複合体異常症、アルツハイマー病、神経変性疾患、軽度認知障害、パーキンソン病、外傷性脳損傷、癌、うつ病、自閉症、偏頭痛、筋萎縮性側索硬化症、睡眠発作、糖尿病、心不全、心筋梗塞、狭心症および肥満からなる群から選択される1種または2種以上である、前記[6]に記載の組成物および用剤。
[8]シトルリン、ロイシン、システイン、タウリン、グルタミンおよびアスパラギン酸からなる群から選択される1種または2種以上のアミノ酸を哺乳動物に摂取させるか、あるいは投与することを含んでなる、ケトン体生成促進方法並びにケトン体生成促進がその治療、予防または改善に有効である疾患または症状の治療方法、予防方法または改善方法。
[9]前記アミノ酸に加えて、中鎖脂肪酸および中鎖脂肪酸エステルのいずれかまたは両方を哺乳動物に摂取させるか、あるいは投与することを含んでなる、前記[8]に記載のケトン体生成促進方法並びに治療方法、予防方法または改善方法。
[10]ケトン体生成促進剤またはケトン体生成促進がその治療、予防または改善に有効である疾患または症状の治療剤、予防剤または改善剤の製造のための、シトルリン、ロイシン、システイン、タウリン、グルタミンおよびアスパラギン酸からなる群から選択される1種または2種以上のアミノ酸の使用。
[11]ケトン体生成促進剤またはケトン体生成促進がその治療、予防または改善に有効である疾患または症状の治療剤、予防剤または改善剤の製造のための、シトルリン、ロイシン、システイン、タウリン、グルタミンおよびアスパラギン酸からなる群から選択される1種または2種以上のアミノ酸と、中鎖脂肪酸および中鎖脂肪酸エステルのいずれかまたは両方との組み合わせの使用。
一緒に摂取ないし投与可能なものとしては、例えば、MCTオイルや1,3-ブタンジオールなどのケトンエステルが挙げられる。
下記実施例において血中βヒドロキシ酪酸濃度は自己検査用βヒドロキシ酪酸測定器(プレシジョンエクシード、アボット社製)を用いて測定した。
下記実施例においてケトン体生成促進は以下のようにして評価した。すなわち、ラットを断食下、尾静脈より採血を行い、血中ケトン体指標であるβヒドロキシ酪酸(bHB)の血中濃度(mmol/L)を測定し初期値(0時間)とした。対照群および実験群に群分けし被験試料を摂取させた後、初期値から6時間後までの血中bHB濃度の推移をグラフ化し、bHBの血中最大濃度(Cmax)および血中濃度−曲線下面積(AUC)を求める参考図を図1Aに示した。各測定時における測定値から初期値(0時間)の測定値を差し引いた値を算出し、これを血中βヒドロキシ酪酸濃度(ΔbHB濃度)の変化量とした(図1B)。次いで、血中βヒドロキシ酪酸濃度(ΔbHB濃度)の変化量について、初期値(0時間)から6時間後までの血中最大濃度(ΔCmax)および血中濃度−曲線下面積(ΔAUC)を算出した(図1B)。
雄性Wistar系ラット(日本SLC株式会社より入手)を1週間馴化後、試験に用いた。一晩の断食下、尾静脈より採血を行い、血中ケトン体指標である血中βヒドロキシ酪酸(bHB)濃度(mmol/L)を測定した。体重およびβヒドロキシ酪酸濃度の平均値がなるべく等しくなるように群分け(各n=8)した。次いで、対照群には10mL/kg体重の水を、実験群には1.0mmоl/kg体重の各種アミノ酸(和光純薬社製)水溶液を経口摂取させた。水または各アミノ酸水溶液を摂取させた直後に中鎖脂肪酸油脂(MCT)であるカプリル酸トリグリセリド(東京化成工業社製)を3.0g/kg体重となるように経口摂取させた。MCT摂取の後、1、2、3、4、5、6時間後に尾静脈より採血を行い、血中βヒドロキシ酪酸濃度を測定した。
雄性Wistar系ラット(日本SLC株式会社より入手)を1週間馴化後、試験に用いた。4時間の断食下、尾静脈より採血を行い(0時間)、血中ケトン体指標である血中βヒドロキシ酪酸(bHB)(mmol/L)を測定した。体重およびβヒドロキシ酪酸濃度の平均値がなるべく等しくなるように群分け(対照群および実験群の3群、各n=8)した。次いで、対照群には10mL/kg体重の水を、実験群には1.5mmоl/kg体重のシトルリン(Cit)または1.5mmоl/kg体重のロイシン(Leu)を経口摂取させた。水、シトルリン水溶液またはロイシン水溶液を摂取させた直後に中鎖脂肪酸油脂(MCT)としてカプリル酸トリグリセリド(東京化成工業社製)を4.5g/kg体重となるように経口摂取させた。MCT摂取の後、1、2、3、4、5、6時間後に尾静脈より採血を行い、血中のβヒドロキシ酪酸濃度を測定した。
雄性Wistar系ラット(日本SLC株式会社より入手)を1週間馴化後、試験に用いた。4時間の断食下、尾静脈より採血を行い(0時間)、血中ケトン体指標である血中βヒドロキシ酪酸濃度(mmol/L)を測定した。体重およびβヒドロキシ酪酸濃度の平均値がなるべく等しくなるように群分け(対照群および実験群の2群、各n=10)した。次いで、対照群には10ml/kg体重の水を、実験群にはそれぞれ1.5mmоl/kg体重、2.25mmоl/kg体重、3.0mmоl/kg体重となるようにシトルリン水溶液を経口摂取させた。水またはシトルリン水溶液を摂取させた直後に中鎖脂肪酸油脂(MCT)としてカプリル酸トリグリセリド(理研ビタミン社製)を4.5g/kg体重となるように経口摂取させた。MCT摂取の後、1、2、3、4、5、6時間後に尾静脈より採血を行い、血中βヒドロキシ酪酸濃度を測定した。実施例1と同様に、初期値(0時間)から6時間後までのβヒドロキシ酪酸(bHB)の血中最大濃度(ΔCmax)および血中濃度−曲線下面積(ΔAUC)を算出し、対照群に対する実験群のβヒドロキシ酪酸の血中最大濃度ΔCmaxの%相対値(%ΔCmax(%))および血中濃度−曲線下面積ΔAUCの%相対値(%ΔAUC(%))を求めた。
Claims (7)
- シトルリン、ロイシン、システイン、タウリン、グルタミンおよびアスパラギン酸からなる群から選択される1種または2種以上のアミノ酸を有効成分として含んでなる、ケトン体生成促進用組成物。
- 中鎖脂肪酸および中鎖脂肪酸エステルのいずれかまたは両方をさらに含んでなる、請求項1に記載の組成物。
- 中鎖脂肪酸エステルが中鎖脂肪酸トリグリセリドである、請求項1または2に記載の組成物。
- アミノ酸(A)の中鎖脂肪酸および中鎖脂肪酸エステル(B)に対するモル比[(A)/(B)]が0.1〜0.5である、請求項2または3に記載の組成物。
- 食品組成物である、請求項1〜4のいずれか一項に記載の組成物。
- ケトン体生成促進がその治療、予防または改善に有効である疾患または症状の治療、予防または改善に用いるための、請求項1〜5のいずれか一項に記載の組成物。
- 前記疾患および症状が、小児てんかん、難治性てんかん、グルコーストランスポーター1(GLUT1)欠損症、ピルビン酸脱水素酵素複合体異常症、アルツハイマー病、神経変性疾患、軽度認知障害、パーキンソン病、外傷性脳損傷、癌、うつ病、自閉症、偏頭痛、筋萎縮性側索硬化症、睡眠発作、糖尿病、心不全、心筋梗塞、狭心症および肥満からなる群から選択される1種または2種以上である、請求項6に記載の組成物。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016161267A JP6935994B2 (ja) | 2016-08-19 | 2016-08-19 | ケトン体生成促進用組成物 |
PCT/JP2017/029587 WO2018034330A1 (ja) | 2016-08-19 | 2017-08-18 | ケトン体生成促進用組成物 |
CN201780049740.6A CN109803646A (zh) | 2016-08-19 | 2017-08-18 | 酮体生成促进用组合物 |
SG10202101629TA SG10202101629TA (en) | 2016-08-19 | 2017-08-18 | Composition for promoting ketone body production |
EP22190716.5A EP4144348A1 (en) | 2016-08-19 | 2017-08-18 | Composition for promoting ketone body production |
CA3033908A CA3033908A1 (en) | 2016-08-19 | 2017-08-18 | Composition for promoting ketone body production |
TW106128061A TWI749050B (zh) | 2016-08-19 | 2017-08-18 | 包含選自瓜胺酸、白胺酸、半胱胺酸、牛磺酸、麩胺酸及天冬胺酸所成群組的1種或2種以上之胺基酸與中鏈脂肪酸及中鏈脂肪酸酯之任一者或兩者之組成物用於人攝取促進酮體生成之使用 |
SG11201900522SA SG11201900522SA (en) | 2016-08-19 | 2017-08-18 | Composition for promoting ketone body production |
US16/326,260 US11224581B2 (en) | 2016-08-19 | 2017-08-18 | Composition for promoting ketone body production |
EP17841552.7A EP3501516A4 (en) | 2016-08-19 | 2017-08-18 | COMPOSITION FOR PROMOTING THE FORMATION OF A KETONE BODY |
US17/542,996 US20220151966A1 (en) | 2016-08-19 | 2021-12-06 | Composition for Promoting Ketone Body Production |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016161267A JP6935994B2 (ja) | 2016-08-19 | 2016-08-19 | ケトン体生成促進用組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018027923A true JP2018027923A (ja) | 2018-02-22 |
JP6935994B2 JP6935994B2 (ja) | 2021-09-15 |
Family
ID=61196762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016161267A Active JP6935994B2 (ja) | 2016-08-19 | 2016-08-19 | ケトン体生成促進用組成物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US11224581B2 (ja) |
EP (2) | EP3501516A4 (ja) |
JP (1) | JP6935994B2 (ja) |
CN (1) | CN109803646A (ja) |
CA (1) | CA3033908A1 (ja) |
SG (2) | SG10202101629TA (ja) |
TW (1) | TWI749050B (ja) |
WO (1) | WO2018034330A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210177025A1 (en) * | 2018-09-24 | 2021-06-17 | Tastes Natural, Llc | Process for isolating taste-modifiers |
US12041951B2 (en) * | 2021-02-26 | 2024-07-23 | Tastes Natural, Llc | Isolated taste-modifier and method of making same |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020070559A1 (en) * | 2018-10-04 | 2020-04-09 | Ajinomoto Co., Inc. | Leucine-enriched ketogenic formulations |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06287138A (ja) * | 1993-04-02 | 1994-10-11 | Green Cross Corp:The | アルツハイマー病予防治療剤 |
JPH09121809A (ja) * | 1995-08-03 | 1997-05-13 | B Braun Melsungen Ag | 栄養用調製物 |
JP2008255033A (ja) * | 2007-04-03 | 2008-10-23 | Meiji Milk Prod Co Ltd | アミノ酸組成物及び飲食物 |
JP2009532496A (ja) * | 2006-04-03 | 2009-09-10 | アクセラ・インコーポレーテッド | 加齢に伴う記憶障害を治療するためのケト原性化合物の使用 |
JP2009261335A (ja) * | 2008-04-25 | 2009-11-12 | Tsujido Chemical Corp | 食品組成物 |
JP2011136948A (ja) * | 2009-12-28 | 2011-07-14 | Nisshin Oillio Group Ltd | うつ病又はうつ状態の予防又は治療用油脂組成物 |
JP2013189437A (ja) * | 2005-07-29 | 2013-09-26 | Tima Foundation | アルコール代謝を和らげる、およびアルコール誘発性疾患のリスクを減少させるための組成物 |
WO2016013617A1 (ja) * | 2014-07-23 | 2016-01-28 | 一般財団法人糧食研究会 | 脳機能改善剤、及び認知機能障害の予防または治療剤 |
JP2016514725A (ja) * | 2013-03-19 | 2016-05-23 | ユニヴァーシティ オブ サウス フロリダ | 高められ且つ継続されるケトーシスを生じさせる組成物および方法 |
US20160175378A1 (en) * | 2013-09-04 | 2016-06-23 | Beth Israel Deaconess Medical Center | New ketogenic diet and its use in treating the critically ill |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008143182A1 (ja) * | 2007-05-17 | 2008-11-27 | Kaneka Corporation | 甘草ポリフェノールを含有する組成物 |
ITRM20100679A1 (it) * | 2010-12-21 | 2012-06-22 | Aniello Antimo D | Acido d-aspartico, acido l-aspartico, loro sali o loro combinazioni per il ripristino dell attività cognitiva e della memoria negli ammalati di alzheimer e in altre demenze senili. |
WO2012113415A1 (en) * | 2011-02-24 | 2012-08-30 | N.V. Nutricia | Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients |
JP6507365B2 (ja) | 2015-03-05 | 2019-05-08 | パナソニックIpマネジメント株式会社 | レンジフード |
JP2016210720A (ja) | 2015-05-07 | 2016-12-15 | 治 江▲崎▼ | 運動機能改善剤、呼吸機能改善剤または認知能改善剤 |
-
2016
- 2016-08-19 JP JP2016161267A patent/JP6935994B2/ja active Active
-
2017
- 2017-08-18 US US16/326,260 patent/US11224581B2/en active Active
- 2017-08-18 CA CA3033908A patent/CA3033908A1/en active Pending
- 2017-08-18 SG SG10202101629TA patent/SG10202101629TA/en unknown
- 2017-08-18 EP EP17841552.7A patent/EP3501516A4/en not_active Withdrawn
- 2017-08-18 SG SG11201900522SA patent/SG11201900522SA/en unknown
- 2017-08-18 TW TW106128061A patent/TWI749050B/zh active
- 2017-08-18 EP EP22190716.5A patent/EP4144348A1/en active Pending
- 2017-08-18 WO PCT/JP2017/029587 patent/WO2018034330A1/ja unknown
- 2017-08-18 CN CN201780049740.6A patent/CN109803646A/zh active Pending
-
2021
- 2021-12-06 US US17/542,996 patent/US20220151966A1/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06287138A (ja) * | 1993-04-02 | 1994-10-11 | Green Cross Corp:The | アルツハイマー病予防治療剤 |
JPH09121809A (ja) * | 1995-08-03 | 1997-05-13 | B Braun Melsungen Ag | 栄養用調製物 |
JP2013189437A (ja) * | 2005-07-29 | 2013-09-26 | Tima Foundation | アルコール代謝を和らげる、およびアルコール誘発性疾患のリスクを減少させるための組成物 |
JP2009532496A (ja) * | 2006-04-03 | 2009-09-10 | アクセラ・インコーポレーテッド | 加齢に伴う記憶障害を治療するためのケト原性化合物の使用 |
JP2008255033A (ja) * | 2007-04-03 | 2008-10-23 | Meiji Milk Prod Co Ltd | アミノ酸組成物及び飲食物 |
JP2009261335A (ja) * | 2008-04-25 | 2009-11-12 | Tsujido Chemical Corp | 食品組成物 |
JP2011136948A (ja) * | 2009-12-28 | 2011-07-14 | Nisshin Oillio Group Ltd | うつ病又はうつ状態の予防又は治療用油脂組成物 |
JP2016514725A (ja) * | 2013-03-19 | 2016-05-23 | ユニヴァーシティ オブ サウス フロリダ | 高められ且つ継続されるケトーシスを生じさせる組成物および方法 |
US20160175378A1 (en) * | 2013-09-04 | 2016-06-23 | Beth Israel Deaconess Medical Center | New ketogenic diet and its use in treating the critically ill |
WO2016013617A1 (ja) * | 2014-07-23 | 2016-01-28 | 一般財団法人糧食研究会 | 脳機能改善剤、及び認知機能障害の予防または治療剤 |
Non-Patent Citations (5)
Title |
---|
EPILEPSIA, vol. 49, no. 8, JPN6021030804, 2008, pages 33 - 36, ISSN: 0004566227 * |
FUNDAMENTAL & CLINICAL PHARMACOLOGY, vol. 27, JPN6021030806, 2013, pages 35 - 50, ISSN: 0004566229 * |
MOL. NUTR. FOOD RES., vol. 58, no. 12, JPN6021030805, 2014, pages 2320 - 2330, ISSN: 0004566228 * |
YEH, Y.: "Ketone body synthesis from leucine by adipose tissue from different sites in the rat", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 233, no. 1, JPN6017037192, 1984, pages 10 - 18, XP024761335, ISSN: 0004468551, DOI: 10.1016/0003-9861(84)90596-4 * |
西園祥子 ほか: "タウリン食ラット肝臓におけるコレステロールエステルの蓄積・分泌低下と脂肪酸酸化の関係", タウリンリサーチ, vol. 1, no. 1, JPN6017037196, 2015, pages 50 - 52, ISSN: 0004468552 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210177025A1 (en) * | 2018-09-24 | 2021-06-17 | Tastes Natural, Llc | Process for isolating taste-modifiers |
US12041951B2 (en) * | 2021-02-26 | 2024-07-23 | Tastes Natural, Llc | Isolated taste-modifier and method of making same |
Also Published As
Publication number | Publication date |
---|---|
SG11201900522SA (en) | 2019-02-27 |
US11224581B2 (en) | 2022-01-18 |
TW201818829A (zh) | 2018-06-01 |
EP3501516A1 (en) | 2019-06-26 |
US20220151966A1 (en) | 2022-05-19 |
EP3501516A4 (en) | 2020-07-29 |
TWI749050B (zh) | 2021-12-11 |
SG10202101629TA (en) | 2021-03-30 |
CN109803646A (zh) | 2019-05-24 |
EP4144348A1 (en) | 2023-03-08 |
WO2018034330A1 (ja) | 2018-02-22 |
JP6935994B2 (ja) | 2021-09-15 |
US20190183828A1 (en) | 2019-06-20 |
CA3033908A1 (en) | 2018-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6255079B2 (ja) | シトルリンおよびアルギニンを含有する即効性血中アルギニン濃度上昇型経口剤 | |
US20100137226A1 (en) | Fatigue-reducing agent | |
EP3115047B1 (en) | Debility preventative | |
KR20140079389A (ko) | 수면의 질 개선제 | |
JP5046174B2 (ja) | アルギニン含有血流増加用組成物 | |
US8921310B2 (en) | Method for accelerating mammalian body fat metabolism | |
JP5294149B2 (ja) | グルタミン含有血流増加用組成物 | |
US20220151966A1 (en) | Composition for Promoting Ketone Body Production | |
JP2008143811A (ja) | 脂質代謝促進組成物 | |
JP2022159178A (ja) | 抗老化用組成物 | |
WO2019181822A1 (ja) | エネルギー代謝促進用組成物 | |
JP7069531B2 (ja) | ピロロキノリンキノン又はその塩と分岐鎖アミノ酸とを含むカプセル | |
JP4523236B2 (ja) | 抗ストレス剤 | |
JP2021536494A (ja) | マグネシウム含有製剤及びその使用 | |
JP7430442B2 (ja) | グレリン受容体の活性化剤 | |
EP3622951B1 (en) | Agent for raising total ketone concentration, oil and fat composition, pharmaceutical composition, and food product composition | |
JPWO2017159741A1 (ja) | 行動体力向上剤 | |
JP2000302677A (ja) | カルニチン自己産生能改善作用を有する医薬および食品・飼料組成物 | |
WO2019022149A1 (ja) | ケトン体生成促進剤 | |
JP2022144737A (ja) | 安静時エネルギー消費量の上昇用又は低下予防用組成物及び呼吸商の低下用又は上昇予防用組成物 | |
TW201320993A (zh) | 使用於調節urat1活性的組成物 | |
JP2005289933A (ja) | アルコール吸収抑制剤およびアルコール吸収抑制用飲食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190807 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200714 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200911 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201112 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210323 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210617 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210617 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210706 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210713 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210810 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210826 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6935994 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |